Skip to main content
. 2026 Jul 13;13:1817500. doi: 10.3389/fmed.2026.1817500

Figure 3.

Panel A shows a table summarizing clinical, histopathological, biochemical, and precipitating factors supporting an HCV-triggered porphyria cutanea tarda diagnosis. Panel B displays a line graph tracking ALT, GGT, and TBil levels from March to October 2024, with a pronounced decline after August. Panel C presents two line graphs: one depicting a decrease in ferritin from 1201 ng/mL in April 2024 to 587 ng/mL in August 2024, and another showing transferrin saturation dropping from 94.7% to 48.2% during the same period, both reflecting changes before and after antiviral therapy.

Diagnostic evaluation and laboratory findings. (A) Summary of clinical, histopathological, and biochemical findings supporting the diagnosis of porphyria cutanea tarda. (B) Longitudinal changes in liver enzymes and bilirubin levels. (C) Changes in iron indices before and after antiviral therapy, showing a marked reduction in ferritin and transferrin saturation.